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Abstract: The most critical step in drug discovery process is target identification. Loss of 
function disease such as cystic fibrosis is caused by impairment of one protein and target 
identification of such diseases becomes a more tedious task. Protein interactions can provide 
an insight of other proteins which could be targeted to affect the regulation of particular 
protein involved in disease. The present study was taken to identify the critical protein which 
could be targeted to affect the regulation of CFTR (Cystic Fibrosis Transmembrane 
Regulator) which is mutated in Cystic Fibrosis using a systems biology network approach 
involving STRING and ClusterONE plugin of Cytoscape. Five proteins namely PDZK1, 
SLC9A3R1, CFTR, CANX and HSPA8 were identified to be the critical proteins which could 
affect the regulation of CFTR. Calnexin (CANX) and HSPA8/HSC70 were also present in 
Cluster 2 obtained by ClusterONE which contains proteins responsible for degradation of 
misfolded protein. Finally HSPA8/HSC70 was selected to be a probable critical target 
protein as it has been reported that abolishing the interaction of F508del-CFTR with 
calnexin (CAS treatment) has no major (positive or negative) effect on ERAD of F508del-
CFTR. Thus, systems biology approach may hold great promise to identify probable 
therapeutic targets. 
 
Keywords: Systems biology, CFTR, Cytoscape, Protein-protein interactions, Potential 
therapeutic target. 
 
Introduction 
Defect in protein trafficking has been recognized as an important mechanism for a growing 
number of inherited human diseases [1]. Cystic fibrosis (CF), an autosomal recessive genetic 
disorder  affecting most critically the lungs, and also the pancreas, liver, and intestine is 
characterized by abnormal transport of chloride and sodium across the epithelium, leading to 
thick, viscous secretions [2]. CF is caused by a mutation in the gene for the protein cystic 
fibrosis transmembrane conductance regulator (CFTR). CFTR regulates the movement of 
chloride and sodium ions across epithelial membranes, such as the alveolar epithelia located 
in the lungs and most mutations in CF patients result in swift intracellular degradation of the 
CFTR protein [3].  
 
The majority of CF cases are caused by nucleotide deletions (ΔF508del CFTR; >75%), 
resulting in CFTR misfolding, or insertion of premature termination codons (~10%), leading 
to unstable mRNA and reduced levels of truncated dysfunctional CFTR [4]. However, in 
many cases, the trafficking-defective mutant protein retains residual function if it can be 
rescued to its final destination [5]. The retention of a misfolded protein in the endoplasmic 
reticulum (ER) is linked to the activity of the cell quality control system [6]. This retention   INT. J. BIOAUTOMATION, 2013, 17(4), 227-240 
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generally causes the absence of the client CFTR protein at its target site, preventing its 
physiological function and leading to abnormal cell homeostasis and functions [5]. 
 
Newer proteomic approaches have shown that CFTR interacts with many other intracellular 
proteins, and the pathophysiologic relevance of these interactions has not been fully 
elucidated. However, this understanding is important for therapeutic interventions, since drugs 
that induce chloride secretion but do not affect other CFTR functions may not address all 
relevant aspects of CF pathophysiology [7]. 
 
Lung disease, which results from chronic infection and inflammation, is the most common 
reason of death in the CF population and thus its treatment is a significant area of CF therapy. 
In the CF lung, activation of the nuclear factor (NF)-κB signaling pathway leads to enhanced 
production of pro-inflammatory mediators, including interleukin (IL)-8. Drugs are being 
developed to treat various proteins involved in this inflammatory cycle which are still their 
clinical trials [8]. Gene therapy trials are on-going which aim to deliver functional CFTR 
genes to the epithelial cells of the CF airway. But in phase 1 studies, gene expression was not 
detected. The UK Cystic Fibrosis Gene Therapy Consortium is currently performing a phase 
1/2 safety study using pGM169/GL67A. These systems utilizing liposomes to promote the 
aerosolized delivery of a DNA plasmid containing the CFTR gene are also being tested for 
their efficiency. 
 
Ensuing the cloning of the CFTR gene in 1989 [9], the focus has now shifted towards the 
identification of candidate critical target proteins and indicators of disease severity. 
Restoration of normal CFTR function is considered to be the foremost therapeutic area as this 
will target the fundamental cause of CF disease rather than just considering the symptoms. 
Various proteins and protein degradation products have been discovered as candidate 
biomarkers of experimental outcome, such as neutrophil elastase and IL-8 [10], degradation 
of lung surfactant protein SP-A [11], urinary desmosine [12] and proline-glycine-proline [13]. 
However, none of these markers has proved adequately robust for routine acceptance in 
clinical trials for cystic fibrosis [14]. 
 
Systems Biology approach aims to find ways to condense and focus varied types of molecular 
data into meaningful perceptions [15]. For cystic fibrosis, the most immediate goal is to 
translate protein-protein interactions involved in the disease in a way that turns these 
perceptions into effective therapeutics targets. Systems biology approach, with combination 
of computational, experimental and observational enquiry, is highly significant to drug 
discovery and the optimization of medical treatment regimens for individual patients [16]. 
 
Protein-protein interactions (PPIs) are involved in most of the essential processes that occur in 
living organisms, such as cellular communication, immunological response, and gene 
expression control. Systematic description of these interactions aids elucidation of targeted 
drug design. Thus, targeting PPI of therapeutic interest with small-molecule compounds is 
becoming the holy grail of drug discovery [17]. The present study was undertaken to identify 
the critical protein which could be targeted to affect the regulation of CFTR which is mutated 
in CF using a systems biology approach. 
 
Materials and methods 
The physical interactions concerning the mutant protein CFTR and other proteins which are 
involved in the pathophysiology of disease were collected using STRING. After the   INT. J. BIOAUTOMATION, 2013, 17(4), 227-240 
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partitioning of the initial network into sub-graphs and intersecting the networks; we identified 
the critica protein, which could be targeted as drug target. 
 
  Databases 
To construct the network, CFTR protein was taken as input protein in STRING database [18] 
to find its direct and functional partners. The network was expanded to find the genes which 
functionally interact with CFTR and can be part of other pathways related to prognosis of 
cystic fibrosis. This online database, Search Tool for the Retrieval of Interacting Genes 
(STRING), provides uniquely comprehensive coverage and ease of access to both 
experimental as well as predicted interaction information. Interactions in STRING are 
provided with a confidence score, and accessory information such as protein domains and 3D 
structures are made available, all within a stable and consistent identifier space. 
 
  Network clustering and merging 
Cytoscape is an open source free platform for visualizing molecular networks and integrating 
with gene expression profiles. Additional features are available as plugins. Plugins are 
available for network and molecular profiling analyses, new layouts, additional file format 
support and connection with databases and searching in large networks [19]. 
 
The division of the resulting PPI network into overlapping sub-graphs of highly 
interconnected nodes was performed using the plugin ClusterONE (Clustering with 
Overlapping Neighbourhood Expansion) of Cytoscape. The algorithm behind the plugin 
ClusterONE works by “growing” dense regions out of small seeds guided by a quality 
function. The quality of a group is assessed by the number of internal edges divided by the 
number of edges connecting nodes of the group. Starting from a single seed, the algorithm 
extends the group step by step with new edges if they increase the quality of a group. An edge 
can be removed when its removal increases the quality of its group. The process stops when it 
is not possible to increase the quality of the groups by adding or removing another edge. 
Finally, sub-graphs smaller than 3 or having a density (number of edges within the cluster 
divided by the number of theoretically possible edges), less than 0.45 and a p-value under 
0.05, are discarded. The density of 0.45 is chosen to get several overlapping sub-graphs 
having good quality. The p-value of one cluster is computed a posteriori with the one-sided 
Mann-Whitney U test performed on the number of intra edges and external boundary edges. 
An intra-edge is between a cluster node and a node within the cluster. An external boundary 
edge is between a cluster node and a node outside the cluster [20].  
 
The four PPI networks involved in folding-maturation, membrane expression, degradation 
and inflammation of CFTR were intersected using Merge network plugin of Cytoscape to find 
the proteins which were common in all four pathways or may be points of connections 
amongst these pathways and thus may be considered as probable drug targets for cystic 
fibrosis. 
 
Results and discussion 
Network and systems biology offer a novel way of approaching drug discovery by developing 
models that consider the global physiological environment of protein targets, and the effects 
of modifying them, without losing the key molecular details. Protein and genetic interaction 
maps can reveal the overall physical and functional landscape of a biological system [21]. 
 
To identify protein target(s) which interact with the protein CFTR, protein-protein interaction 
(PPI) network was obtained using STRING database (Fig. 1) using CFTR as the input protein.   INT. J. BIOAUTOMATION, 2013, 17(4), 227-240 
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The network consisted of 71 nodes and 812 edges. The network was expanded up to seventy 
one nodes as more expanding of network resulted in increase in the number of nonspecific 
interactions, which would affect the analysis and specificity of the PPI network.  
 
 
Fig. 1 PPI network of proteins interacting directly and  
functionally with CFTR obtained from STRING. 
 
As cystic fibrosis is mainly concerned with misfolding of protein, the study of proteins 
involved in folding and maturation, membrane expression, degradation of CFTR and 
inflammation associated with cystic fibrosis could be used to short-list the probable drug 
targets which can be targeted to treat cystic fibrosis. Therefore, four other PPIs networks 
involved in folding-maturation, membrane expression, degradation and inflammation of 
CFTR were generated using STRING (Figs. 2-5). 
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Fig. 2 PPI network of proteins involved in folding of CFTR generated in STRING 
 
Six proteins namely CFTR, HSP70, Hsp40, Hdj-1, HspBP1 [22] and Calnexin [23], which 
have been reported to be involved in folding and maturation of the CFTR were used to obtain 
PPI network from the STRING database. A total of thirty five proteins were identified as the 
interacting partners of the main proteins which are involved in CFTR folding and maturation 
(Fig. 2). 
 
Rab-4, Rab-11A [24], Ezrin [25] and EBP50 [26], that have been reported to be involved in 
CFTR membrane expression were taken as input proteins in the STRING database to find 
functional associations of these proteins and the network was expanded to find the PPIs. 
Eighty one proteins were found to be the interacting partners of the main proteins involved in 
CFTR membrane expression (Fig. 3). 
 
Sec61 [30], were taken as input proteins to form the third network in the STRING database 
and the network was expanded and 44 proteins were recognized as the relating partners of the 
main proteins which are involved in CFTR degradation (Fig. 4). 
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Fig. 3 PPI network of proteins involved in membrane expression  
of CFTR generated in STRING 
 
Interleukin family proteins i.e., IL-1, IL-8, IL-6 and CFTR were reported by Bonfield et al. 
[31] to be involved in CFTR degradation. These were taken as input to build the fourth 
network in the STRING database and 59 proteins were identified as the interacting partners of 
the main proteins which are involved in CFTR inflammation (Fig. 5). 
 
As the PPI network involving interactions of CFTR returned by STRING was too large to 
yield any meaningful information, therefore it was necessary to divide it into highly 
connected sub-graphs that represent functional modules, or protein sub-complexes. So, the 
network was divided into overlapping sub-graphs of highly interconnected nodes with the 
Cytoscape plugin ClusterONE.   INT. J. BIOAUTOMATION, 2013, 17(4), 227-240 
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Fig. 4 PPI network of proteins involved in degradation of CFTR generated in STRING 
 
The CFTR network was sub-divided into 6 sub-graphs (Clusters 1 to 6) (Table 1) by 
ClusterONE, of which five have p-values under 0.05 and good quality scores (Table 2). In a 
PPI network, sub-graphs of highly interconnected proteins can be considered as protein 
complexes or functional modules. Five clusters namely Cluster 1, 2, 3, 4 and 5 (Table 2) 
which have quality scores greater than 0.5 and density greater than 0.25 were selected for 
further analysis. Cluster 1 consisted of proteins mainly involved in the activation of various 
channels, membrane stabilization and membrane expression of CFTR. Cluster 2 contains 
proteins that interact with misfolded CFTR protein. These proteins are responsible for 
targeting the misfolded protein to degradation pathway.  
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Fig. 5 PPI network of proteins involved in inflammation of CFTR generated in STRING 
 
Cluster 3 and 4 mainly consisted of adaptor proteins which help in assembly of subunits of 
various complexes and proteins involved in transport through endoplasmic reticulum and 
degradation of misfolded proteins, respectively. So it can be hypothesized that some of the 
degradation proteins are in Cluster 4 along with Cluster 2 because they might have more 
associations with the proteins present in endoplasmic reticulum which are responsible for 
protein transport. This may suggest that there are various barriers to differentiate between 
properly folded and misfolded proteins when they are transported through ER to their 
destinations. Cluster 5 consisted of proteins responsible for trafficking across the Golgi. Out 
of all the clusters returned by ClusterONE, Cluster 2 contained proteins responsible for 
degradation of misfolded protein. From the proteins of Cluster 2 those proteins may be 
selected whose inhibition could prevent the degradation of the misfolded protein, so that 
misfolded protein could reach the membrane and activity of CFTR could be enhanced 
resulting in retention of the activity of the CFTR channel. 
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Table 1. Sub-graphs of CFTR network obtained from STRING  
analyzed using Cytoscape plugin ClusterONE 
Cluster  Protein members of the sub-graphs 
1  OPRK1 LPAR2 SLC9A3R2 EZR AKAP12 PODXL ADRB2 PTH1R 
SLC26A6 SGK1 PIK3CA PTEN SLC9A3 PDZK1IP1 NF2 MSN PDZK1 
SLC34A1 SLC22A5 SLC9A3R1 PDGFRB SCARB1 
2  BAG2 DNAJA1 VCP DNAJC6 RNF5 PDIA3 P4HB PSMD2 HSPA5 STUB1 
HSPA8 DERL1 HSP90AA1 BAG1 HSPBP1 DNAJB1 BAG3 CD3D SELS 
CANX EDEM1 CFTR 
3  AKAP3 PDE4A AKAP13 PRKAR2A AKAP1 MAP2 CREB1 AKAP11 
AKAP5 AKAP12 ADRB2 AKAP6 AKAP9 PDE3A LIPE 
4  VCP PDIA3 P4HB PSMD2 HSPA5 DERL1 CD3D SELS CANX EDEM1 
5  MAP2 CREB1 SGK1 
6  DNAJC5 DNAJC6 VAMP1 STXBP1 VAMP2 KCNB1 UNC13B CPLX1 
DNAJA3 SYTL4 SNAP25 SYT1 SLC6A1 STX1A SNAP23 HSPA8 
 
Table 2. Characteristics of the CFTR PPI sub-networks  
obtained with Cytoscape plugin ClusterONE 
Cluster Nodes Density Quality  p-value 
1 22  0.84  0.703  2.047×10
-7 
2 22  1.186  0.772  1.689×10
-7 
3 15  0.914  0.65  1.457×10
-4 
4 10  2.022  0.562  0.002 
5  3  1.66  0.152  0.975 
6 16  1.317  0.693  3.067×10
-5 
 
To find the proteins which were common in all four pathways or may be points of connection 
amongst these pathways, the four PPI networks involved in folding and maturation, 
membrane expression, degradation and inflammation of CFTR were intersected. Using the 
Merge networks plugin of Cytoscape, the following network combinations were generated 
(Fig. 6): 
•  Intersection of membrane expression and folding with maturation network; 
•  Intersection of membrane expression with inflammation network; 
•  Intersection of membrane expression with degradation network; 
•  Intersection of folding with degradation network; 
•  Intersection of folding with inflammation network; 
•  Intersection of inflammation response with degradation network. 
 
It was observed that five proteins were common in all the six intersected networks. These 
were PDZK1, SLC9A3R1, CFTR, CANX and HSPA8/HSC70. Out of these calnexin 
(CANX) and HSPA8/HSC70 were also present in Cluster 2, which contains proteins 
responsible for degradation of misfolded protein. One of the proteins responsible for rescuing 
CFTR was Calnexin. CalnexinRNAi studies by [32], suggest that abrogating the interaction of 
F508del-CFTR with calnexin (CAS treatment) has no major (positive or negative) effect on 
ERAD (Endoplasmic-reticulum-associated protein degradation) of F508del-CFTR, and 
therefore may not be suitable for therapeutic intervention.   INT. J. BIOAUTOMATION, 2013, 17(4), 227-240 
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a )        b )  
     
c )        d )  
     
e )        f )  
Fig. 6 Intersected Networks obtained through Merge network plugin of cytoscape:  
a) intersection of membrane expression and folding with maturation network;  
b) intersection of membrane expression with inflammation response network;  
c) intersection of membrane expression with degradation network; d) intersection of folding 
with degradation network; e) intersection of folding within flammation network;  
f) intersection of inlammation response with degradation network   INT. J. BIOAUTOMATION, 2013, 17(4), 227-240 
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The other protein which could be considered as possible therapeutic intervention target is 
HSPA8/HSC70. Proper folding of CFTR in the endoplasmic reticulum is vastly dependent on 
a molecular chaperone HSPA8/HSC70. HSPA8/HSC70 protein is constitutively expressed in 
many cell types and has numerous functions such as protein folding, protein translocation, 
degradation of misfolded proteins, and regulation of assembly and disassembly of protein 
complexes [33]. 
 
F508del-CFTR interacts with HSPA8/HSC70, CHIP that recognizes the C-terminus of 
HSPA8/HSC70 and has the ubiquitin ligase activity, targets the mutant for proteasomal 
degradation by promoting its ubiquitination. Therefore, CHIP acts as a protein that converts 
HSPA8/HSC70 from a protein-folding factor to a degradation factor in the ERQC 
(endoplasmic reticulum quality control) system [5]. Importantly, F508del-CFTR rescued on 
the plasma membrane has a chloride channel function, although the rescued mutant is less 
stable than the wild-type protein and thus small molecules that block degradation of the 
mutant have potential applications in cystic ﬁbrosis therapeutics [7]. It has been suggested 
that inhibition of HSPA8/HSC70 activity can rescue defective cellular processing of mutant 
CFTR [33-34], therefore could be probable target for therapeutic intervention. 
 
Thus using systems biology approach we have been able to identify HSPA8/HSC70 as a 
potential drug target for cystic fibrosis which is a critical molecular chaperon involved in cell 
signalling survival and protein homeostasis. Although the targeting of the core mediator of the 
protein homeostasis can be quite challenging due to its widespread cellular roles, but it can be 
further studied as the drug target based on the success of targeting other molecular chaperons 
such as HSP90 for cancer [35]. 
 
Conclusion 
Protein network approach holds the promise of providing a theoretical framework for 
studying the wealth of biological data being generated on the potential drug targets and 
considers the global physiological environment of protein targets. Using this approach we 
have been able to identify a potential drug target (HSPA8/HSC70) for therapeutic intervention 
of cystic fibrosis. 
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